ReviewVaccine2022
Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
Paul Moss et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ReviewVaccine2022
Paul Moss et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.